Antiviral agent ribavirin, which was recently approved as an aerosol by the food and medicines for the treatment of severe respiratory syncytial virus infections among hospitalized children not in need of controlled breathing. Ribavirin is different from other antiviral drugs as a range of actions, and on ways to apply.
The question arises about the benefits of treatment compared with the potential toxicity of an unknown drug and the possibility of using ribavirin infant children in the Ventilator attached abstract does not recommend the appointment of the drug such patients. It is necessary to take into account that pregnant women and staff, which cares for infants receiving ribavirin are at risk of contact with the drug. Doctors also need to know about the high cost of ribavirin.
Ribavirin. Ribavirin in the form of an aerosol is the first specific tool against respiratory syncytial virus. This is a synthetic nucleoside analogue (1-ribafurazonil-1 ,2,4-triazol-Z-karboksamid), recalled guanozin and inosine. It is believed that it inhibits the synthesis of viral proteins, but does not include much of the DNA and RNA host cells.
A pregnant rodents experienced its teratogenicity, but it did not pregnant baboon.
Probable casual contact, hospital staff and visitors with ribavirin aerosol in the care of treating babies. The staff who care for such children throughout the change (at least 25 hours of contact within 5 days without a break), was examined and ribavirin was not found either in serum or in urine. Even in patients receiving the drug aerosol directly within 5 hours, its concentration in plasma is not reached a mikromolya per liter. Oral ribavirin to receive 1.0 grams daily for more than 7 days adults would cause a temporary decline in the hematocrit to 20%. However, adult volunteers who received ribavirin in the form of an aerosol through a mask for 12 hours. a day for three days, there was no toxicity or side effects.